Pradžia › Ūmi mieloidinė leukemija › Pennsylvania
Ūmi mieloidinė leukemija klinikiniai tyrimai Pennsylvania
45 tyrimai dėl Ūmi mieloidinė leukemija ieško dalyvių vietose Pennsylvania.
Miestai Pennsylvania
- Philadelphia34 tyrimai
- Pittsburgh18 tyrimai
- Harrisburg8 tyrimai
- Allentown8 tyrimai
- Scranton6 tyrimai
- Reading5 tyrimai
Oficialus tyrimo tekstas (anglų kalba)
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- Thomas Jefferson University Hospital, Philadelphia
Renkami dalyviai2 fazė
Amžius 60 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT07437950Assessment of Geriatric Evaluations Impact on New AML Guidance
- Abramson Cancer Center at University of Pennsylvania, Philadelphia
Renkami dalyviaiStebimasis tyrimas
Amžius 50 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT05909501Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- Geisinger Medical Center, Danville
- ir dar 7
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Amžius nuo 40 iki 75 · Visoms lytims · Atnaujinta 2026-10-02 · NCT05334069Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital of Philadelphia, Philadelphia
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 0 iki 38 · Visoms lytims · Atnaujinta 2026-10-01 · NCT06131801Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Milton S Hershey Medical Center, Hershey
- ir dar 4
Renkami dalyviai2 fazė
Amžius nuo 18 iki 59 · Visoms lytims · Atnaujinta 2026-09-28 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Thomas Jefferson University, Philadelphia
- Fox Chase Cancer Center, Philadelphia
- University of Pittsburgh Medical Center, Pittsburgh
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Milton S Hershey Medical Center, Hershey
- ir dar 6
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT05564390A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
- Children's Hospital of Philadelphia, Philadelphia
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Renkami dalyviai1 fazė
Iki 21 metų · Visoms lytims · Atnaujinta 2026-09-23 · NCT07012044Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Milton S Hershey Medical Center, Hershey
- ir dar 4
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-22 · NCT06317649Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- Geisinger Medical Center, Danville
- Thomas Jefferson University Hospital, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
- ir dar 1
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-22 · NCT06672146Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Milton S Hershey Medical Center, Hershey
- ir dar 6
Renkami dalyviai2 fazė
Amžius nuo 18 iki 59 · Visoms lytims · Atnaujinta 2026-09-22 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Children's Hospital, Hershey
- ir dar 3
Renkami dalyviai3 fazė
6 Months – 21 Years · Visoms lytims · Atnaujinta 2026-09-17 · NCT04293562A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- University of Pennsylvania, Philadelphia
Renkami dalyviai1/2 fazė
30 Days · Visoms lytims · Atnaujinta 2026-09-16 · NCT04065399Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
- Spoknwrd Clinical Trials Inc., Easton
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-16 · NCT06824168A Study of BGB-11417 in Participants With Myeloid Malignancies
- Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-14 · NCT04771130Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
- UPENN Perelman Center for Advanced Medicine, Philadelphia
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-14 · NCT06846606Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- Geisinger Medical Center, Danville
- Children's Hospital of Philadelphia, Philadelphia
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Renkami dalyviai3 fazė
Amžius nuo 1 iki 25 · Visoms lytims · Atnaujinta 2026-09-04 · NCT07022678A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
- Cancer Care Associates of York, York
Renkami dalyviaiStebimasis tyrimas
Amžius 0 ir vyresni · Visoms lytims · Atnaujinta 2026-09-02 · NCT07154823Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- US-Pittsburgh PA-PITT, Pittsburgh
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-02 · NCT06652438Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
- US-Pittsburgh PA-PITT, Pittsburgh
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-01 · NCT07223814The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Children's Hospital, Hershey
- ir dar 3
Renkami dalyviai1/2 fazė
Iki 22 metų · Visoms lytims · Atnaujinta 2026-08-25 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Children's Hospital of Philadelphia, Philadelphia
Renkami dalyviai3 fazė
29 Days – 21 Years · Visoms lytims · Atnaujinta 2026-08-24 · NCT05183035Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Pennsylvania, Philadelphia
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-20 · NCT07007312Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies
- UMPC Hillman Cancer Center, Pittsburgh
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-18 · NCT07565220Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
- UPMC Hillman Cancer Center, Pittsburgh
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-11 · NCT06529731L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
- University of Pennsylvania, Philadelphia
Renkami dalyviai2/3 fazė
Amžius nuo 18 iki 80 · Visoms lytims · Atnaujinta 2026-08-05 · NCT06788756Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Children's Hospital of Philadelphia, Philadelphia
Renkami dalyviai1 fazė
Amžius nuo 1 iki 30 · Visoms lytims · Atnaujinta 2026-08-03 · NCT06177067Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
- Penn Medicine Abramson Cancer Center, Philadelphia
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-10 · NCT05442216CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML
- University of Pennsylvania, Philadelphia
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-09 · NCT05945849CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
- Children's Hospital of Philadelphia, Philadelphia
Renkami dalyviai
Iki 25 metų · Visoms lytims · Atnaujinta 2026-07-08 · NCT03810196CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia
- Children's Hospital of Philadelphia, Philadelphia
Renkami dalyviai1 fazė
Amžius nuo 0 iki 29 · Visoms lytims · Atnaujinta 2026-07-07 · NCT07464951A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Penn State Milton S. Hershey Cancer Center, Hershey
- Children's Hospital of Philadelphia, Philadelphia
- Children's Hospital of Pittsburgh, Pittsburgh
- ir dar 3
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2026-07-06 · NCT01351545Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- Penn Medicine - Abramson Cancer Center Perelman, Philadelphia
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-06-24 · NCT04068597SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
- University of Pennsylvania, Philadelphia
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-05-14 · NCT06222580Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
- Pennsylvania State University Hershey Medical Center, Hershey
Renkami dalyviai1 fazė
Iki 21 metų · Visoms lytims · Atnaujinta 2026-04-22 · NCT05101551Massage Impact on Sleep in Pediatric Oncology
- Children's Hospital of Philadelphia, Philadelphia
Renkami dalyviai
Amžius nuo 12 iki 21 · Visoms lytims · Atnaujinta 2026-04-15 · NCT06892158A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Sidney Kimmel Comprehensive Cancer Center, Philadelphia
- Allegheny Health Network, Pittsburgh
Renkami dalyviai1/2 fazė
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-03-24 · NCT04988555Phase IB/II of CPX-351 for Relapse Prevention in AML
- University of Pennsylvania, Philadelphia
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-03-23 · NCT04990102A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
- Thomas Jefferson University Hospital, Philadelphia
Renkami dalyviai1 fazė
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-03-16 · NCT06994676A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Hospital of the University of Pennsylvania, Philadelphia
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-03-13 · NCT05735184Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.